JP2024513781A - クローナルなネオ抗原の同定及びその使用 - Google Patents

クローナルなネオ抗原の同定及びその使用 Download PDF

Info

Publication number
JP2024513781A
JP2024513781A JP2023558897A JP2023558897A JP2024513781A JP 2024513781 A JP2024513781 A JP 2024513781A JP 2023558897 A JP2023558897 A JP 2023558897A JP 2023558897 A JP2023558897 A JP 2023558897A JP 2024513781 A JP2024513781 A JP 2024513781A
Authority
JP
Japan
Prior art keywords
tumor
clonal
mutation
probability
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513781A5 (enExample
Inventor
ロス，アンドリュー
プリンツ ツー サルム－ホルストマール，マクシミリアン
チュン チャン，フォン
Original Assignee
アキレス セラピューティクス ユーケー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アキレス セラピューティクス ユーケー リミテッド filed Critical アキレス セラピューティクス ユーケー リミテッド
Publication of JP2024513781A publication Critical patent/JP2024513781A/ja
Publication of JP2024513781A5 publication Critical patent/JP2024513781A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Primary Health Care (AREA)
  • Molecular Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
JP2023558897A 2021-04-01 2022-04-01 クローナルなネオ抗原の同定及びその使用 Pending JP2024513781A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2104715.4A GB202104715D0 (en) 2021-04-01 2021-04-01 Identification of clonal neoantigens and uses thereof
GB2104715.4 2021-04-01
PCT/EP2022/058793 WO2022207925A1 (en) 2021-04-01 2022-04-01 Identification of clonal neoantigens and uses thereof

Publications (2)

Publication Number Publication Date
JP2024513781A true JP2024513781A (ja) 2024-03-27
JP2024513781A5 JP2024513781A5 (enExample) 2025-04-28

Family

ID=75883641

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558897A Pending JP2024513781A (ja) 2021-04-01 2022-04-01 クローナルなネオ抗原の同定及びその使用

Country Status (10)

Country Link
US (2) US11504398B2 (enExample)
EP (1) EP4313125A1 (enExample)
JP (1) JP2024513781A (enExample)
KR (1) KR20230165259A (enExample)
CN (1) CN117120080A (enExample)
AU (1) AU2022251011A1 (enExample)
CA (1) CA3213222A1 (enExample)
GB (1) GB202104715D0 (enExample)
IL (1) IL306136A (enExample)
WO (1) WO2022207925A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202104715D0 (en) * 2021-04-01 2021-05-19 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
GB202202880D0 (en) 2022-03-02 2022-04-13 Achilles Therapeutics Uk Ltd Methods for peptide synthesis
GB202205147D0 (en) 2022-04-07 2022-05-25 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
EP4681208A1 (en) 2023-03-17 2026-01-21 T-Cypher Bio Ltd Prediction of immunogenicity
GB202307096D0 (en) 2023-05-12 2023-06-28 Achilles Therapeutics Uk Ltd Method
WO2024256485A1 (en) 2023-06-15 2024-12-19 Achilles Therapeutics Uk Limited Identification of neoantigen peptides
GB202407727D0 (en) 2024-05-31 2024-07-17 Ucl Business Ltd Reporters constructs, systems and assays

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160298185A1 (en) * 2013-12-05 2016-10-13 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
US20190172582A1 (en) * 2017-12-01 2019-06-06 Illumina, Inc. Methods and systems for determining somatic mutation clonality
CN111785322A (zh) * 2019-12-30 2020-10-16 杭州慕谷基因科技有限公司 一种结肠腺癌基因组变异与肿瘤进化关系的研究方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2882867A1 (en) 2012-08-10 2015-06-17 The Broad Institute, Inc. Methods and apparatus for analyzing and quantifying dna alterations in cancer
BR112015025460B1 (pt) * 2013-04-07 2024-01-02 The Broad Institute, Inc. Método para a produção de uma vacina personalizada contra a neoplasia para um indivíduo diagnosticado como tendo uma neoplasia, vacina personalizada e uso da mesma
JP6740127B2 (ja) 2013-12-06 2020-08-12 ザ・ブロード・インスティテュート・インコーポレイテッド 新生物ワクチン用製剤
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
ES2836273T3 (es) * 2015-04-27 2021-06-24 Cancer Research Tech Ltd Método para el tratamiento del cáncer
TWI750122B (zh) 2015-06-09 2021-12-21 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
GB201516047D0 (en) * 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
JP6904953B2 (ja) * 2015-12-03 2021-07-21 アレス トレーディング ソシエテ アノニム 細胞クローン性を決定する方法
CA3050109A1 (en) * 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigens and uses thereof for treating cancer
WO2018170578A1 (en) * 2017-03-20 2018-09-27 Ontario Institute For Cancer Research (Oicr) Cancer risk based on tumour clonality
EP3651791A1 (en) * 2017-07-14 2020-05-20 The Francis Crick Institute Limited Analysis of hla alleles in tumours and the uses thereof
IL259392A (en) * 2018-05-15 2018-08-01 Yeda Res & Dev Vaccination with cancer neoantigens
US11189361B2 (en) * 2018-06-28 2021-11-30 International Business Machines Corporation Functional analysis of time-series phylogenetic tumor evolution tree
GB202104715D0 (en) 2021-04-01 2021-05-19 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
GB202205147D0 (en) * 2022-04-07 2022-05-25 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160298185A1 (en) * 2013-12-05 2016-10-13 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
US20190172582A1 (en) * 2017-12-01 2019-06-06 Illumina, Inc. Methods and systems for determining somatic mutation clonality
CN111785322A (zh) * 2019-12-30 2020-10-16 杭州慕谷基因科技有限公司 一种结肠腺癌基因组变异与肿瘤进化关系的研究方法

Also Published As

Publication number Publication date
CN117120080A (zh) 2023-11-24
WO2022207925A1 (en) 2022-10-06
GB202104715D0 (en) 2021-05-19
IL306136A (en) 2023-11-01
US11504398B2 (en) 2022-11-22
CA3213222A1 (en) 2022-10-06
KR20230165259A (ko) 2023-12-05
US12548651B2 (en) 2026-02-10
US20230071113A1 (en) 2023-03-09
AU2022251011A1 (en) 2023-10-05
EP4313125A1 (en) 2024-02-07
US20220323499A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
Litchfield et al. Meta-analysis of tumor-and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
US12548651B2 (en) Identification of clonal neoantigens and uses thereof
Budczies et al. Tumour mutational burden: clinical utility, challenges and emerging improvements
Bailey et al. Tracking cancer evolution through the disease course
Kiyotani et al. Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma
EP3576781B1 (en) Neoantigens and uses thereof for treating cancer
Miao et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Anagnostou et al. Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer
US20230154563A1 (en) Detection of Human Leukocyte Antigen Loss of Heterozygosity
AU2016319316A1 (en) "immune checkpoint intervention" in cancer
Morazán-Fernández et al. In silico pipeline to identify tumor-specific antigens for cancer immunotherapy using exome sequencing data
CN116580771A (zh) 预测肿瘤新抗原的方法和装置
US20250218535A1 (en) Identification of clonal neoantigens and uses thereof
Lo et al. Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies
Barroux et al. Evolutionary and immune microenvironment dynamics during neoadjuvant treatment of esophageal adenocarcinoma
AU2021454223A1 (en) Detection of human leukocyte antigen loss of heterozygosity
WO2023146978A2 (en) Systems and methods for determining t-cell cross-reactivity between antigens
JP2025534267A (ja) 対立遺伝子特異的発現
Esperança-Martins et al. Machine learning-based analysis of genomic and transcriptomic data unveils sarcoma clusters with superlative prognostic and predictive value
CA3268552A1 (en) Allele specific expression
Gurjao Leveraging passenger mutations to guide cancer treatment and prevention
Borden Immune Recognition and Sculpting of Neoantigens in Human Tumors
Moore et al. A conserved subset of cold tumors responsive to immune checkpoint blockade
Sivakumar High-Throughput computational methods in sequencing and immuno-oncology: Identifying immunogenic mutations and T-cell receptor repertoire dynamics
Spassova Prognostic and predictive biomarkers in Merkel cell carcinoma

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260408